Skip to main content
. Author manuscript; available in PMC: 2010 Mar 1.
Published in final edited form as: Lab Invest. 2010 Jan 11;90(3):414–425. doi: 10.1038/labinvest.2009.138

Figure 3.

Figure 3

Expression level of FBXO32 in ovarian cancer cell lines treated with 5-aza-2′-deoxycytidine (5azaDC) or trichostatin A (TSA). Ovarian cancer cells were either treated with (A) 0.5 μM 5-azaDC for 72 hours or (B) TSA for 12 hours. Expression FBXO32 was determined by quantitative real time RT-PCR and compared to the DMSO treated control. Each bar represents mean ± SD of relative expression level of duplicate experiments.